Complement activation during OKT3 treatment: A possible explanation for respiratory side effects
- 1 May 1993
- journal article
- Published by Elsevier in Kidney International
- Vol. 43 (5) , 1140-1149
- https://doi.org/10.1038/ki.1993.160
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatmentJournal of Clinical Immunology, 1992
- IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATIONTransplantation, 1990
- Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient in vivo T cell activationEuropean Journal of Immunology, 1990
- Muromonab CD3Drugs, 1989
- Tissue Destruction by NeutrophilsNew England Journal of Medicine, 1989
- PROPHYLACTIC USE OF OKT3 MONOCLONAL ANTIBODY IN CADAVER KIDNEY RECIPIENTS UTILIZATION OF OKT3 AS THE SOLE IMMUNOSUPPRESSIVE AGENTTransplantation, 1986
- A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal TransplantsNew England Journal of Medicine, 1985
- Advantages of rat monoclonal antibodiesImmunology Today, 1983
- Role of Complement Activation in a Model of Adult Respiratory Distress SyndromeJournal of Clinical Investigation, 1980
- Release of Inflammatory Mediators from Stimulated NeutrophilsNew England Journal of Medicine, 1980